Page last updated: 2024-11-07

conessine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

conessine : A steroid alkaloid that is con-5-enine substituted by a N,N-dimethylamino group at position 3. It has been isolated from the plant species of the family Apocynaceae. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID441082
CHEMBL ID191703
CHEBI ID27965
SCHEMBL ID791146
MeSH IDM0050088

Synonyms (68)

Synonym
BIDD:ER0525
nsc-119994
neriine
con-5-enine, 3.beta.-(dimethylamino)-
konessin
roquessine
BPBIO1_000700
con-5-enin-3-amine, n,n-dimethyl-, (3beta)-
conkurchine, n,18-dihydrotrimethyl-
conesina [inn-spanish]
con-5-enine, 3beta-(dimethylamino)-
conessinum [inn-latin]
3beta-(dimethylamino)con-5-ene
brn 4702160
(3-beta)-n,n-dimethylcon-5-enin-3-amine
conessine [inn]
nsc 119994
einecs 208-897-2
3beta-(dimethylamino)con-5-enine
PRESTWICK_692
cas-546-06-5
BSPBIO_000636
PRESTWICK3_000638
PRESTWICK2_000638
546-06-5
wrightine
conessine
C06545
NCGC00095844-01
NCGC00092388-01
PRESTWICK0_000638
SPBIO_002855
PRESTWICK1_000638
NCGC00092388-03
conessinum
CHEBI:27965 ,
n,n-dimethylcon-5-enin-3beta-amine
(1r,2s,5s,6s,9r,12s,13r,16s)-n,n,6,7,13-pentamethyl-7-azapentacyclo[10.8.0.0^{2,9}.0^{5,9}.0^{13,18}]icos-18-en-16-amine
bdbm27193
CHEMBL191703
HMS1569P18
HMS2096P18
((2s,5s,12s,16s,1r,9r,13r)-6,7,13-trimethyl-7-azapentacyclo[10.8.0.0<2,9>.0<5, 9>.0<13,18>]icos-18-en-16-yl)dimethylamine
ST066907
dtxsid6046000 ,
tox21_111531
dtxcid4026000
conesina
ez38j9bbdf ,
unii-ez38j9bbdf
conessine [mi]
tox21_111531_1
NCGC00092388-05
SCHEMBL791146
AKOS024283367
A1-00780
n,n-dimethyl-con-5-enin-3-amine
mfcd00016752
gtpl8981
conessine, >=97% (hplc)
Q5159518
F82154
MS-25590
NCGC00092388-15
(1r,2s,5s,6s,9r,12s,13r,16s)-n,n,6,7,13-pentamethyl-7-azapentacyclo[10.8.0.02,9.05,9.013,18]icos-18-en-16-amine
5-conenin-3beta-dimethylamine
HY-107566
GLXC-26648

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
"A new, simple, sensitive, precise and robust high-performance thin layer chromatographic (HPTLC) method was developed for the estimation of conessine in herbal extracts and pharmaceutical dosage forms."( High-performance thin layer chromatography method for estimation of conessine in herbal extract and pharmaceutical dosage formulations.
Agrawal, RK; Jain, PK; Kaur, AD; Ravichandran, V, 2008
)
0.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
antibacterial agentA substance (or active part thereof) that kills or slows the growth of bacteria.
antimalarialA drug used in the treatment of malaria. Antimalarials are usually classified on the basis of their action against Plasmodia at different stages in their life cycle in the human.
H3-receptor antagonistA histamine antagonist that selectively binds to but does not activate histamine H3 receptors, thereby blocking the actions of endogenous histamine.
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
steroid alkaloid
tertiary amino compoundA compound formally derived from ammonia by replacing three hydrogen atoms by organyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (15)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
15-lipoxygenase, partialHomo sapiens (human)Potency31.62280.012610.691788.5700AID887
TDP1 proteinHomo sapiens (human)Potency16.36010.000811.382244.6684AID686978
AR proteinHomo sapiens (human)Potency20.54240.000221.22318,912.5098AID1259243; AID743042; AID743054
thyroid stimulating hormone receptorHomo sapiens (human)Potency2.51190.001318.074339.8107AID926; AID938
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency29.84930.001530.607315,848.9004AID1224848; AID1224849
estrogen nuclear receptor alphaHomo sapiens (human)Potency29.84930.000229.305416,493.5996AID743079
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency0.095219.739145.978464.9432AID1159509
lethal factor (plasmid)Bacillus anthracis str. A2012Potency6.30960.020010.786931.6228AID912
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Alpha-2A adrenergic receptorHomo sapiens (human)Ki0.66070.00010.807410.0000AID365347
Alpha-2C adrenergic receptorHomo sapiens (human)Ki0.01050.00030.483410.0000AID365346
Histamine H2 receptorHomo sapiens (human)Ki6.67160.00062.197310.0000AID1798786; AID365344
Histamine H1 receptorHomo sapiens (human)Ki6.67160.00000.511010.0000AID1798786; AID365343
Histamine H4 receptorHomo sapiens (human)Ki6.67160.00060.478710.0000AID1798786; AID365345
Histamine H3 receptorRattus norvegicus (Norway rat)Ki2.74600.00010.29638.5110AID1798786; AID320917; AID365340; AID365342; AID421583
Histamine H3 receptorHomo sapiens (human)Ki3.33880.00010.33998.5110AID1798786; AID365339; AID365341; AID409910; AID421582
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (63)

Processvia Protein(s)Taxonomy
positive regulation of cytokine productionAlpha-2A adrenergic receptorHomo sapiens (human)
DNA replicationAlpha-2A adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
Ras protein signal transductionAlpha-2A adrenergic receptorHomo sapiens (human)
Rho protein signal transductionAlpha-2A adrenergic receptorHomo sapiens (human)
female pregnancyAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of cell population proliferationAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2A adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-2A adrenergic receptorHomo sapiens (human)
actin cytoskeleton organizationAlpha-2A adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of cell migrationAlpha-2A adrenergic receptorHomo sapiens (human)
activation of protein kinase activityAlpha-2A adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2A adrenergic receptorHomo sapiens (human)
cellular response to hormone stimulusAlpha-2A adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2A adrenergic receptorHomo sapiens (human)
vasodilationAlpha-2A adrenergic receptorHomo sapiens (human)
glucose homeostasisAlpha-2A adrenergic receptorHomo sapiens (human)
fear responseAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of potassium ion transportAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of MAP kinase activityAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion-dependent exocytosisAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretionAlpha-2A adrenergic receptorHomo sapiens (human)
intestinal absorptionAlpha-2A adrenergic receptorHomo sapiens (human)
thermoceptionAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of lipid catabolic processAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of membrane protein ectodomain proteolysisAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion transportAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretion involved in cellular response to glucose stimulusAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of uterine smooth muscle contractionAlpha-2A adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-inhibiting adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
phospholipase C-activating adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of wound healingAlpha-2A adrenergic receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion transmembrane transporter activityAlpha-2A adrenergic receptorHomo sapiens (human)
regulation of smooth muscle contractionAlpha-2C adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2C adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-2C adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2C adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2C adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2C adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2C adrenergic receptorHomo sapiens (human)
positive regulation of neuron differentiationAlpha-2C adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretionAlpha-2C adrenergic receptorHomo sapiens (human)
gastric acid secretionHistamine H2 receptorHomo sapiens (human)
immune responseHistamine H2 receptorHomo sapiens (human)
positive regulation of vasoconstrictionHistamine H2 receptorHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayHistamine H2 receptorHomo sapiens (human)
chemical synaptic transmissionHistamine H2 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerHistamine H2 receptorHomo sapiens (human)
inflammatory responseHistamine H1 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayHistamine H1 receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayHistamine H1 receptorHomo sapiens (human)
memoryHistamine H1 receptorHomo sapiens (human)
visual learningHistamine H1 receptorHomo sapiens (human)
regulation of vascular permeabilityHistamine H1 receptorHomo sapiens (human)
positive regulation of vasoconstrictionHistamine H1 receptorHomo sapiens (human)
regulation of synaptic plasticityHistamine H1 receptorHomo sapiens (human)
cellular response to histamineHistamine H1 receptorHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayHistamine H1 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerHistamine H1 receptorHomo sapiens (human)
chemical synaptic transmissionHistamine H1 receptorHomo sapiens (human)
inflammatory responseHistamine H4 receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationHistamine H4 receptorHomo sapiens (human)
biological_processHistamine H4 receptorHomo sapiens (human)
regulation of MAPK cascadeHistamine H4 receptorHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayHistamine H4 receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayHistamine H4 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerHistamine H4 receptorHomo sapiens (human)
chemical synaptic transmissionHistamine H4 receptorHomo sapiens (human)
neurotransmitter secretionHistamine H3 receptorHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayHistamine H3 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerHistamine H3 receptorHomo sapiens (human)
chemical synaptic transmissionHistamine H3 receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayHistamine H3 receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (17)

Processvia Protein(s)Taxonomy
alpha2-adrenergic receptor activityAlpha-2A adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2A adrenergic receptorHomo sapiens (human)
protein kinase bindingAlpha-2A adrenergic receptorHomo sapiens (human)
alpha-1B adrenergic receptor bindingAlpha-2A adrenergic receptorHomo sapiens (human)
alpha-2C adrenergic receptor bindingAlpha-2A adrenergic receptorHomo sapiens (human)
thioesterase bindingAlpha-2A adrenergic receptorHomo sapiens (human)
heterotrimeric G-protein bindingAlpha-2A adrenergic receptorHomo sapiens (human)
protein homodimerization activityAlpha-2A adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-2A adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2A adrenergic receptorHomo sapiens (human)
norepinephrine bindingAlpha-2A adrenergic receptorHomo sapiens (human)
guanyl-nucleotide exchange factor activityAlpha-2A adrenergic receptorHomo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2C adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2C adrenergic receptorHomo sapiens (human)
alpha-2A adrenergic receptor bindingAlpha-2C adrenergic receptorHomo sapiens (human)
protein homodimerization activityAlpha-2C adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-2C adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2C adrenergic receptorHomo sapiens (human)
guanyl-nucleotide exchange factor activityAlpha-2C adrenergic receptorHomo sapiens (human)
histamine receptor activityHistamine H2 receptorHomo sapiens (human)
G protein-coupled serotonin receptor activityHistamine H2 receptorHomo sapiens (human)
neurotransmitter receptor activityHistamine H2 receptorHomo sapiens (human)
histamine receptor activityHistamine H1 receptorHomo sapiens (human)
G protein-coupled serotonin receptor activityHistamine H1 receptorHomo sapiens (human)
neurotransmitter receptor activityHistamine H1 receptorHomo sapiens (human)
histamine receptor activityHistamine H4 receptorHomo sapiens (human)
G protein-coupled serotonin receptor activityHistamine H4 receptorHomo sapiens (human)
G protein-coupled acetylcholine receptor activityHistamine H4 receptorHomo sapiens (human)
histamine receptor activityHistamine H3 receptorHomo sapiens (human)
G protein-coupled acetylcholine receptor activityHistamine H3 receptorHomo sapiens (human)
G protein-coupled serotonin receptor activityHistamine H3 receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (16)

Processvia Protein(s)Taxonomy
cytoplasmAlpha-2A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
basolateral plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
neuronal cell bodyAlpha-2A adrenergic receptorHomo sapiens (human)
axon terminusAlpha-2A adrenergic receptorHomo sapiens (human)
presynaptic active zone membraneAlpha-2A adrenergic receptorHomo sapiens (human)
dopaminergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
postsynaptic density membraneAlpha-2A adrenergic receptorHomo sapiens (human)
glutamatergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
GABA-ergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
receptor complexAlpha-2A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
cytoplasmAlpha-2C adrenergic receptorHomo sapiens (human)
endosomeAlpha-2C adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2C adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2C adrenergic receptorHomo sapiens (human)
plasma membraneHistamine H2 receptorHomo sapiens (human)
synapseHistamine H2 receptorHomo sapiens (human)
plasma membraneHistamine H2 receptorHomo sapiens (human)
dendriteHistamine H2 receptorHomo sapiens (human)
cytosolHistamine H1 receptorHomo sapiens (human)
plasma membraneHistamine H1 receptorHomo sapiens (human)
synapseHistamine H1 receptorHomo sapiens (human)
dendriteHistamine H1 receptorHomo sapiens (human)
plasma membraneHistamine H1 receptorHomo sapiens (human)
plasma membraneHistamine H4 receptorHomo sapiens (human)
plasma membraneHistamine H4 receptorHomo sapiens (human)
dendriteHistamine H4 receptorHomo sapiens (human)
synapseHistamine H4 receptorHomo sapiens (human)
plasma membraneHistamine H3 receptorHomo sapiens (human)
presynapseHistamine H3 receptorHomo sapiens (human)
plasma membraneHistamine H3 receptorHomo sapiens (human)
synapseHistamine H3 receptorHomo sapiens (human)
dendriteHistamine H3 receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (101)

Assay IDTitleYearJournalArticle
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID343387Inhibition of Trypanosoma cruzi recombinant trypanothione reductase at 200 uM2008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
The use of natural product scaffolds as leads in the search for trypanothione reductase inhibitors.
AID320917Displacement of N-[3H]methylhistamine from histamine H3 receptor in rat cortex2008Bioorganic & medicinal chemistry letters, Feb-15, Volume: 18, Issue:4
A new family of H3 receptor antagonists based on the natural product Conessine.
AID365370Ratio of drug level in brain to plasma at 1 mg/kg, ip after 24 hrs2008Journal of medicinal chemistry, Sep-11, Volume: 51, Issue:17
The alkaloid conessine and analogues as potent histamine H3 receptor antagonists.
AID421583Displacement of [3H]N-alpha methyl histamine from rat cortical membrane histamine H3 receptor2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Design of a new histamine H3 receptor antagonist chemotype: (3aR,6aR)-5-alkyl-1-aryl-octahydropyrrolo[3,4-b]pyrroles, synthesis, and structure-activity relationships.
AID343389Inhibition of Trypanosoma cruzi recombinant trypanothione reductase at 800 uM2008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
The use of natural product scaffolds as leads in the search for trypanothione reductase inhibitors.
AID365345Displacement of [3H]histamine from human histamine H4 receptor expressed in HEK cells2008Journal of medicinal chemistry, Sep-11, Volume: 51, Issue:17
The alkaloid conessine and analogues as potent histamine H3 receptor antagonists.
AID365357Antagonist activity at rat full length histamine H3 receptor assessed as inhibition of (R)-alpha-methylhistamine-induced intracellular calcium release by FLIPR2008Journal of medicinal chemistry, Sep-11, Volume: 51, Issue:17
The alkaloid conessine and analogues as potent histamine H3 receptor antagonists.
AID365346Displacement of [3H]rauwolscine from human adrenergic alpha 2C4 receptor expressed in mouse LTK- cells2008Journal of medicinal chemistry, Sep-11, Volume: 51, Issue:17
The alkaloid conessine and analogues as potent histamine H3 receptor antagonists.
AID365366Drug level in rat brain at 1 mg/kg, ip after 5 hrs2008Journal of medicinal chemistry, Sep-11, Volume: 51, Issue:17
The alkaloid conessine and analogues as potent histamine H3 receptor antagonists.
AID365339Displacement of [3H]NAMH from human full length histamine H3 receptor expressed in rat C6 cells2008Journal of medicinal chemistry, Sep-11, Volume: 51, Issue:17
The alkaloid conessine and analogues as potent histamine H3 receptor antagonists.
AID365350Displacement of [3H]LY278584 from 5HT3 receptor in rat frontal cortex2008Journal of medicinal chemistry, Sep-11, Volume: 51, Issue:17
The alkaloid conessine and analogues as potent histamine H3 receptor antagonists.
AID1578835Inhibition of MexAB/OprM nalB mutant in Pseudomonas aeruginosa PAO1 K1455 assessed as potentiation of cefotaxime-induced antibacterial activity by measuring cefotaxime MIC at 20 ug/ml incubated for 18 hrs by CLSI based broth microtitre dilution method (Rv2019Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19
Antibiotic Adjuvants: Make Antibiotics Great Again!
AID365379Toxicity in rat assessed as CNS side effects at 1.3 to 13 mg/kg, ip2008Journal of medicinal chemistry, Sep-11, Volume: 51, Issue:17
The alkaloid conessine and analogues as potent histamine H3 receptor antagonists.
AID365352Antagonist activity at human full length histamine H3 receptor expressed in HEK cells assessed as inhibition of [35S]gammaGTP binding relative to control2008Journal of medicinal chemistry, Sep-11, Volume: 51, Issue:17
The alkaloid conessine and analogues as potent histamine H3 receptor antagonists.
AID1578833Inhibition of MexAB/OprM nalB mutant in Pseudomonas aeruginosa PAO1 K1455 assessed as potentiation of rifampin-induced antibacterial activity by measuring novobiocin MIC at 20 ug/ml incubated for 18 hrs by CLSI based broth microtitre dilution method (Rvb 2019Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19
Antibiotic Adjuvants: Make Antibiotics Great Again!
AID1578831Inhibition of MexAB/OprM nalB mutant in Pseudomonas aeruginosa PAO1 K1455 assessed as potentiation of levofloxacin-induced antibacterial activity by measuring levofloxacin MIC at 20 ug/ml incubated for 18 hrs by CLSI based broth microtitre dilution method2019Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19
Antibiotic Adjuvants: Make Antibiotics Great Again!
AID248554In vitro antiplasmodial activity for chloroquine-resistant Plasmodium falciparum FcB1 2005Bioorganic & medicinal chemistry letters, May-16, Volume: 15, Issue:10
Isolation, characterization and antiplasmodial activity of steroidal alkaloids from Funtumia elastica (Preuss) Stapf.
AID343392Antileishmanial activity against Leishmania amazonensis MHOM/BR/76/LTB-012 promastigotes at 100 uM after 72 hrs by alamar blue assay2008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
The use of natural product scaffolds as leads in the search for trypanothione reductase inhibitors.
AID409910Displacement of [125I]iodoproxyfan from human recombinant histamine H3 receptor expressed in CHO-K1 cells2008Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18
Piperidine variations in search for non-imidazole histamine H(3) receptor ligands.
AID365369Ratio of drug level in brain to plasma at 1 mg/kg, ip after 5 hrs2008Journal of medicinal chemistry, Sep-11, Volume: 51, Issue:17
The alkaloid conessine and analogues as potent histamine H3 receptor antagonists.
AID343385Inhibition of Trypanosoma cruzi recombinant trypanothione reductase at 85 uM2008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
The use of natural product scaffolds as leads in the search for trypanothione reductase inhibitors.
AID365363Drug level in rat blood at 1 mg/kg, ip after 5 hrs2008Journal of medicinal chemistry, Sep-11, Volume: 51, Issue:17
The alkaloid conessine and analogues as potent histamine H3 receptor antagonists.
AID365358Antagonist activity at histamine H3 receptor in guinea pig ileum assessed as inhibition of (R)-alpha-methylhistamine-induced response2008Journal of medicinal chemistry, Sep-11, Volume: 51, Issue:17
The alkaloid conessine and analogues as potent histamine H3 receptor antagonists.
AID365361Plasma concentration in rat at 1 mg/kg, ip after 24 hrs2008Journal of medicinal chemistry, Sep-11, Volume: 51, Issue:17
The alkaloid conessine and analogues as potent histamine H3 receptor antagonists.
AID365341Displacement of [3H]NAMH from histamine H3 receptor in human cortex2008Journal of medicinal chemistry, Sep-11, Volume: 51, Issue:17
The alkaloid conessine and analogues as potent histamine H3 receptor antagonists.
AID365362Drug level in rat blood at 1 mg/kg, ip after 1 hr2008Journal of medicinal chemistry, Sep-11, Volume: 51, Issue:17
The alkaloid conessine and analogues as potent histamine H3 receptor antagonists.
AID421580Clearance in rat CNS after 24 hrs assessed as compound remaining2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Design of a new histamine H3 receptor antagonist chemotype: (3aR,6aR)-5-alkyl-1-aryl-octahydropyrrolo[3,4-b]pyrroles, synthesis, and structure-activity relationships.
AID1578834Inhibition of MexAB/OprM nalB mutant in Pseudomonas aeruginosa PAO1 K1455 assessed as potentiation of tetracycline-induced antibacterial activity by measuring tetracycline MIC at 20 ug/ml incubated for 18 hrs by CLSI based broth microtitre dilution method2019Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19
Antibiotic Adjuvants: Make Antibiotics Great Again!
AID365348Displacement of [3H]LY278584 from 5HT1 receptor in rat frontal cortex2008Journal of medicinal chemistry, Sep-11, Volume: 51, Issue:17
The alkaloid conessine and analogues as potent histamine H3 receptor antagonists.
AID365376Selectivity ratio for human adrenergic alpha 2C4 receptor over human H3 receptor2008Journal of medicinal chemistry, Sep-11, Volume: 51, Issue:17
The alkaloid conessine and analogues as potent histamine H3 receptor antagonists.
AID365342Displacement of [3H]NAMH from histamine H3 receptor in rat cortex2008Journal of medicinal chemistry, Sep-11, Volume: 51, Issue:17
The alkaloid conessine and analogues as potent histamine H3 receptor antagonists.
AID365364Drug level in rat blood at 1 mg/kg, ip after 24 hrs2008Journal of medicinal chemistry, Sep-11, Volume: 51, Issue:17
The alkaloid conessine and analogues as potent histamine H3 receptor antagonists.
AID421582Displacement of [3H]N-alpha methyl histamine from human cloned histamine H3 receptor expressed in C6 cells2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Design of a new histamine H3 receptor antagonist chemotype: (3aR,6aR)-5-alkyl-1-aryl-octahydropyrrolo[3,4-b]pyrroles, synthesis, and structure-activity relationships.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1578832Inhibition of MexAB/OprM nalB mutant in Pseudomonas aeruginosa PAO1 K1455 assessed as potentiation of novobiocin-induced antibacterial activity by measuring novobiocin MIC at 20 ug/ml incubated for 18 hrs by CLSI based broth microtitre dilution method (Rv2019Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19
Antibiotic Adjuvants: Make Antibiotics Great Again!
AID343388Inhibition of Trypanosoma cruzi recombinant trypanothione reductase at 400 uM2008Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14
The use of natural product scaffolds as leads in the search for trypanothione reductase inhibitors.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID365368Ratio of drug level in brain to plasma at 1 mg/kg, ip after 1 hr2008Journal of medicinal chemistry, Sep-11, Volume: 51, Issue:17
The alkaloid conessine and analogues as potent histamine H3 receptor antagonists.
AID365349Displacement of [3H]LY278584 from 5HT2 receptor in rat frontal cortex2008Journal of medicinal chemistry, Sep-11, Volume: 51, Issue:17
The alkaloid conessine and analogues as potent histamine H3 receptor antagonists.
AID247510Cytotoxicity against rat L-6 cell line2005Bioorganic & medicinal chemistry letters, May-16, Volume: 15, Issue:10
Isolation, characterization and antiplasmodial activity of steroidal alkaloids from Funtumia elastica (Preuss) Stapf.
AID365356Antagonist activity at human full length histamine H3 receptor expressed in HEK293 cells assessed as inhibition of (R)-alpha-methylhistamine-induced intracellular calcium release by FLIPR2008Journal of medicinal chemistry, Sep-11, Volume: 51, Issue:17
The alkaloid conessine and analogues as potent histamine H3 receptor antagonists.
AID365365Drug level in rat brain at 1 mg/kg, ip after 1 hr2008Journal of medicinal chemistry, Sep-11, Volume: 51, Issue:17
The alkaloid conessine and analogues as potent histamine H3 receptor antagonists.
AID365340Displacement of [3H]NAMH from rat full length histamine H3 receptor expressed in rat C6 cells2008Journal of medicinal chemistry, Sep-11, Volume: 51, Issue:17
The alkaloid conessine and analogues as potent histamine H3 receptor antagonists.
AID365360Plasma concentration in rat at 1 mg/kg, ip after 5 hrs2008Journal of medicinal chemistry, Sep-11, Volume: 51, Issue:17
The alkaloid conessine and analogues as potent histamine H3 receptor antagonists.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1578830Inhibition of MexAB/OprM nalB mutant in Pseudomonas aeruginosa PAO1 K1455 assessed as potentiation of erythromycin-induced antibacterial activity by measuring erythromycin MIC at 20 ug/ml incubated for 18 hrs by CLSI based broth microtitre dilution method2019Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19
Antibiotic Adjuvants: Make Antibiotics Great Again!
AID365347Displacement of [3H]rauwolscine from human adrenergic alpha 2C10 receptor expressed in mouse LTK- cells2008Journal of medicinal chemistry, Sep-11, Volume: 51, Issue:17
The alkaloid conessine and analogues as potent histamine H3 receptor antagonists.
AID365344Displacement of [3H]tiotidine from human histamine H2 receptor2008Journal of medicinal chemistry, Sep-11, Volume: 51, Issue:17
The alkaloid conessine and analogues as potent histamine H3 receptor antagonists.
AID365367Drug level in rat brain at 1 mg/kg, ip after 24 hrs2008Journal of medicinal chemistry, Sep-11, Volume: 51, Issue:17
The alkaloid conessine and analogues as potent histamine H3 receptor antagonists.
AID252951Selectivity Index is expressed as the ratio of cytotoxicity (IC50) against rat L-6 cell line to that of antiplasmodial activity (IC50) of chloroquine-resistant strain FcB1 of Plasmodium falciparum2005Bioorganic & medicinal chemistry letters, May-16, Volume: 15, Issue:10
Isolation, characterization and antiplasmodial activity of steroidal alkaloids from Funtumia elastica (Preuss) Stapf.
AID365355Antagonist activity at rat full length histamine H3 receptor expressed in HEK cells assessed as inhibition of forskolin-induced intracellular calcium release by SPA2008Journal of medicinal chemistry, Sep-11, Volume: 51, Issue:17
The alkaloid conessine and analogues as potent histamine H3 receptor antagonists.
AID365354Antagonist activity at human full length histamine H3 receptor expressed in rat C6 cells assessed as inhibition of forskolin-induced cAMP release by SPA2008Journal of medicinal chemistry, Sep-11, Volume: 51, Issue:17
The alkaloid conessine and analogues as potent histamine H3 receptor antagonists.
AID365343Displacement of [3H]mepyramine from human histamine H1 receptor2008Journal of medicinal chemistry, Sep-11, Volume: 51, Issue:17
The alkaloid conessine and analogues as potent histamine H3 receptor antagonists.
AID365353Antagonist activity at rat full length histamine H3 receptor expressed in rat C6 cells assessed as inhibition of [35S]gammaGTP binding relative to control2008Journal of medicinal chemistry, Sep-11, Volume: 51, Issue:17
The alkaloid conessine and analogues as potent histamine H3 receptor antagonists.
AID365359Plasma concentration in rat at 1 mg/kg, ip after 1 hr2008Journal of medicinal chemistry, Sep-11, Volume: 51, Issue:17
The alkaloid conessine and analogues as potent histamine H3 receptor antagonists.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID365351Selectivity ratio for human H4 receptor over human histamine H3 receptor2008Journal of medicinal chemistry, Sep-11, Volume: 51, Issue:17
The alkaloid conessine and analogues as potent histamine H3 receptor antagonists.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1798786Radioligand Binding Assay from Article 10.1021/jm8003625: \\The alkaloid conessine and analogues as potent histamine H3 receptor antagonists.\\2008Journal of medicinal chemistry, Sep-11, Volume: 51, Issue:17
The alkaloid conessine and analogues as potent histamine H3 receptor antagonists.
AID1346095Human H2 receptor (Histamine receptors)2015Pharmacological reviews, Jul, Volume: 67, Issue:3
International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors.
AID1346107Human H3 receptor (Histamine receptors)2015Pharmacological reviews, Jul, Volume: 67, Issue:3
International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors.
AID1346055Human H4 receptor (Histamine receptors)2015Pharmacological reviews, Jul, Volume: 67, Issue:3
International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors.
AID1346037Human H1 receptor (Histamine receptors)2015Pharmacological reviews, Jul, Volume: 67, Issue:3
International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (74)

TimeframeStudies, This Drug (%)All Drugs %
pre-199034 (45.95)18.7374
1990's0 (0.00)18.2507
2000's10 (13.51)29.6817
2010's22 (29.73)24.3611
2020's8 (10.81)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (3.75%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other77 (96.25%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]